Document Type

Patent

Publication Date

12-16-2008

Abstract

Disclosed is an ATPase-deficient dominant-negative mutant NS3 protein of hepatitis C virus inhibits activity of the wild-type NS3 protein and inhibits replication of hepatitis C virus (HCV). The solved crystal structure of a multi-enzyme NS3 complex on a DNA substrate is also provided. Also provided is a method of inhibiting HCV replication in cells infected with HCV involving administering to the cells a dominant-negative mutant NS3 protein. Also, it provides peptides and agents that inhibit HCV replication and methods of identifying agents that inhibit HCV replication.

Department

Chemistry & Biochemistry

Patent Number

US7465537

Application Number

US20060246421

Application Published

11-2-2006

Application Filed

5-1-2005

Assignee

Board of Trustees of the University of Arkansas (Little Rock, AR)

Comments

STATEMENT OF GOVERNMENT SUPPORT Development of this invention was supported by grants P20 RR15569, P20 RR016460, and R01 AI060563 from the National Institutes of Health and funding from U.S. Department of Agriculture. The United States government has certain rights in this invention.

Joshua Sakon, Department of Chemistry and Biochemistry, University of Arkansas, Fayetteville, AR
Jeff Zhiqiang Lu, Department of Chemistry and Biochemistry, University of Arkansas, Fayetteville, AR

Share

COinS